Bio China 2012

Follow Us

Facebook Twitter YouTube LinkedIn

Visit | Read all BIO Business Links



The Return of the Biotech IPO

It‘s not just the volume of IPOs that is making this summer a victory for hibernating private biotechs and their VC backers; it is the details of the offerings in terms of price, performance, and type of biotech making the leap onto the public stage. In the past five years, we have not seen average offering prices land above expectations, but 2013 is breaking this trend. Price performance is also impressive, with a number of IPOs hovering near 2x the offering price. Rounding out these two positives for valuation is the return of the formerly taboo Phase I and Pre-Clinical IPOs a qualitative signal of strength.

Another interesting fact about the recent IPOs: all biotech IPOs since the signing of the JOBS Act in April 2012 have used the new emerging growth company provisions allowed by the new law. Both company management and investors are now experiencing the benefits of the less-strict pre-IPO environment. For the full article on IPOs, read more at

Want to hear from the CEOs and investors making the headlines? Join us at the 12th Annual BIO Investor Forum (October 8-9th, 2013 in San Francisco) where we will feature two panels on the public markets: an investor perspective and an in depth discussion with company management making the private to public transition. The BIO Investor Forum is the must attend event for companies setting their sights on IPO. In fact, 71% of the 2013 companies that have gone public have attended past Business Investor Forums.


Add to your contacts to ensure email delivery.
Not displaying correctly? View this email in a browser.
If you received this message from a colleague, or would like to
receive information on our full spectrum of events, please click here.